AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36858756 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist-Assisted Self-Help Internet-Based Intervention (online CBT intervention)
Number of subjects: 136
Study 36858765 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy for Seasonal Affective Disorder (CBT-SAD)
Number of subjects: 174
Study 36858765 — intervention group
Group type: EXPERIMENTAL
Intervention: Light Therapy
Number of subjects: 174
Study 36858787 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic CD7-CAR T cells
Number of subjects: 0
Study 36859250 — intervention group
Group type: EXPERIMENTAL
Intervention: 'Have a Say' programme (dyadic advance care planning intervention)
Number of subjects: 36
Study 36859250 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study 36859316 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalmefene 0.25 µg/kg
Number of subjects: 520
Study 36859316 — intervention group
Group type: COMPARATOR
Intervention: 0.9% NaCl solution (control)
Number of subjects: 520
Study 36859391 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnea (OSA) defined as an apnea hypopnea index (AHI) ≥ 15 events/hour
Number of subjects: 1927
Study 36859391 — intervention group
Group type: COMPARATOR
Intervention: No OSA
Number of subjects: 1927
Study 36859391 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior stroke
Number of subjects: 1927
Study 36859437 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradialytic Resistance Training (IRT) for 12 weeks (EXG)
Number of subjects: 90
Study 36859437 — intervention group
Group type: COMPARATOR
Intervention: Control group (no IRT) for 12 weeks (CNG)
Number of subjects: 90
Study 36859467 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral triheptanoin at a dose of 1 g/Kg/day, providing near 35% of total caloric intake.
Number of subjects: 6
Study 36859467 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum tolerated dose of triheptanoin at 45% of daily caloric intake for each age group.
Number of subjects: 6
Study 36859467 — intervention group
Group type: EXPERIMENTAL
Intervention: Triheptanoin treatment.
Number of subjects: 6
Study 36859514 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigated inherited risk factors for thrombosis in 4 patients
Number of subjects: 11
Study 36859514 — intervention group
Group type: EXPERIMENTAL
Intervention: Acquired risk factors
Number of subjects: 11
Study 36859619 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 754091 (anti-PD-1) and BI 754111 (anti-LAG-3)
Number of subjects: 6
Study 36860093 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 vaccination
Number of subjects: 0
Study 36860093 — intervention group
Group type: COMPARATOR
Intervention: Unvaccinated adolescents and caregivers
Number of subjects: 0
Study 36860093 — intervention group
Group type: EXPERIMENTAL
Intervention: Child's age
Number of subjects: 0
Study 36860093 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver education (Economic Hardship Index score)
Number of subjects: 0
Study 36860268 — intervention group
Group type: EXPERIMENTAL
Intervention: Elotuzumab plus pomalidomide and dexamethasone (EPd)
Number of subjects: 117
Study 36860268 — intervention group
Group type: COMPARATOR
Intervention: Pomalidomide and dexamethasone (Pd)
Number of subjects: 117
Study 36860319 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab-based treatment regimen
Number of subjects: 0
Study 36860772 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone bruise volume
Number of subjects: 60
Study 36860772 — intervention group
Group type: EXPERIMENTAL
Intervention: International Knee Documentation Committee (IKDC-2000) score
Number of subjects: 60
Study 36860772 — intervention group
Group type: EXPERIMENTAL
Intervention: ACL-Return to Sport after Injury (ACL-RSI) score
Number of subjects: 60
Study 36860772 — intervention group
Group type: EXPERIMENTAL
Intervention: Objective functional performance battery
Number of subjects: 60
Study 36860772 — intervention group
Group type: EXPERIMENTAL
Intervention: Graft reinjury rate
Number of subjects: 60
Study 36860772 — intervention group
Group type: EXPERIMENTAL
Intervention: Level of return to sport/activity
Number of subjects: 60
Study 36860772 — intervention group
Group type: EXPERIMENTAL
Intervention: Single Assessment Numeric Evaluation (SANE)
Number of subjects: 60
Study 36861013 — intervention group
Group type: EXPERIMENTAL
Intervention: Arbaclofen extended-release 80 mg/day
Number of subjects: 323
Study 36861013 — intervention group
Group type: EXPERIMENTAL
Intervention: Arbaclofen extended-release
Number of subjects: 323
Study 36861013 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 323
Study 36861044 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma sTREM-1 and monocyte HLA-DR measured at D1/D2, D3/D4, and D6/D8
Number of subjects: 116
Study 36861044 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased mHLA-DR at D6/D8
Number of subjects: 116
Study 36861085 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribociclib + Aromatase Inhibitor (AI)
Number of subjects: 0
Study 36861085 — intervention group
Group type: COMPARATOR
Intervention: Abemaciclib + Aromatase Inhibitor (AI)
Number of subjects: 0
Study 36861188 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban 2.5 mg (single dose) administered using two pediatric formulations: 0.1 mg sprinkle capsule (age <28 days) and 0.4 mg/ml solution (age 28 days to <18 years); dose range 1.08-2.19 mg/mL.
Number of subjects: 0
Study 36861269 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascularized bone graft
Number of subjects: 45
Study 36861269 — intervention group
Group type: COMPARATOR
Intervention: Non-vascularized iliac crest graft
Number of subjects: 45
Study 36861346 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant von Willebrand factor (rVWF) therapy, administered as long-term routine twice weekly prophylaxis.
Number of subjects: 0
Study 36861346 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant von Willebrand factor (rVWF) therapy.
Number of subjects: 0
Study 36861433 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybutynin 5 mg and Reboxetine 6 mg (oxy-reb)
Number of subjects: 15
Study 36861433 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 36861447 — intervention group
Group type: EXPERIMENTAL
Intervention: Platinum-containing chemotherapy
Number of subjects: 189
Study 36861447 — intervention group
Group type: EXPERIMENTAL
Intervention: Platinum-free chemotherapy
Number of subjects: 189
Study 36861945 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS combined with cognitive training
Number of subjects: 38
Study 36861945 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS combined with cognitive training
Number of subjects: 38
Study 36861976 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (400 mg by mouth twice daily on day 1 followed by 200 mg by mouth twice daily on days 2 to 5)
Number of subjects: 0
Study 36861976 — intervention group
Group type: COMPARATOR
Intervention: Placebo (oral placebo with the same schedule)
Number of subjects: 0
Study 36862168 — intervention group
Group type: EXPERIMENTAL
Intervention: D-VCd
Number of subjects: 60
Study 36862168 — intervention group
Group type: COMPARATOR
Intervention: VCd
Number of subjects: 60
Study 36862181 — intervention group
Group type: EXPERIMENTAL
Intervention: Location on the foot (distal location)
Number of subjects: 0
Study 36862181 — intervention group
Group type: COMPARATOR
Intervention: Proximal locations (thigh, leg)
Number of subjects: 0
Study 36862181 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal melanomas (mainly on the foot)
Number of subjects: 0
Study 36862314 — intervention group
Group type: EXPERIMENTAL
Intervention: Connecting and Reflecting Experience (CARE) program
Number of subjects: 32
Study 36862361 — intervention group
Group type: EXPERIMENTAL
Intervention: Apremilast
Number of subjects: 50
Study 36862461 — intervention group
Group type: EXPERIMENTAL
Intervention: Scheduled SMS text messaging (SM)
Number of subjects: 120
Study 36862461 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Support (SS) with SMS text messaging reminders
Number of subjects: 120
Study 36862461 — intervention group
Group type: COMPARATOR
Intervention: Routine antenatal care (ANC; control)
Number of subjects: 120
Study 36862463 — intervention group
Group type: EXPERIMENTAL
Intervention: Trust/respect plus symptom feedback
Number of subjects: 185
Study 36862463 — intervention group
Group type: COMPARATOR
Intervention: Symptom feedback only
Number of subjects: 185
Study 36862472 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral couple therapy (CBCT)
Number of subjects: 108
Study 36862472 — intervention group
Group type: COMPARATOR
Intervention: Topical lidocaine
Number of subjects: 108
Study 36862574 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotion-oriented coping
Number of subjects: 150
Study 36862574 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysfunctional coping
Number of subjects: 150
Study 36862574 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-focused strategies
Number of subjects: 150
Study 36862648 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led diabetes self-management education and long-term ongoing support
Number of subjects: 0
Study 36862648 — intervention group
Group type: COMPARATOR
Intervention: Diabetes self-management education (control)
Number of subjects: 0
Study 36862681 — intervention group
Group type: COMPARATOR
Intervention: Female group (n = 1679)
Number of subjects: 6613
Study 36862681 — intervention group
Group type: COMPARATOR
Intervention: Male group (n = 4934)
Number of subjects: 6613
Study 36862693 — intervention group
Group type: EXPERIMENTAL
Intervention: In-phase bilateral exercises of the upper limbs (30-60 minutes/session, 3 sessions/week for 12 weeks)
Number of subjects: 5
Study 36862693 — intervention group
Group type: EXPERIMENTAL
Intervention: In-phase bilateral exercises
Number of subjects: 5
Study 36862754 — intervention group
Group type: EXPERIMENTAL
Intervention: Accountable Care (AC) - enhanced monitoring and supervision
Number of subjects: 815
Study 36862754 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (SC) - existing supervisors
Number of subjects: 815
Study 36862966 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid biopsy (FoundationOne Liquid CDx)
Number of subjects: 1416
Study 36862966 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidental findings of high-risk CH through liquid biopsy
Number of subjects: 1416
Study 36862975 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 36
Study 36863094 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-986156 + nivolumab
Number of subjects: 292
Study 36863094 — intervention group
Group type: COMPARATOR
Intervention: BMS-986156
Number of subjects: 292
Study 36863094 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-986156 ± nivolumab
Number of subjects: 292
Study 36863106 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant treatment
Number of subjects: 0
Study 36863106 — intervention group
Group type: EXPERIMENTAL
Intervention: Loudness dependence of auditory evoked potential (LDAEP)
Number of subjects: 0
Study 36863287 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care HCV RNA testing, linkage to nursing care, and peer-supported engagement/delivery of treatment
Number of subjects: 101
Study 36863292 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Group (IG)
Number of subjects: 80
Study 36863292 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 80
Study 36863386 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-2 g of ferric carboxymaltose intravenously
Number of subjects: 202
Study 36863386 — intervention group
Group type: COMPARATOR
Intervention: Three tablets of 200 mg of oral ferrous fumarate daily
Number of subjects: 202
Study 36863390 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-food elimination diet (6FED)
Number of subjects: 129
Study 36863390 — intervention group
Group type: COMPARATOR
Intervention: 1-food elimination diet (1FED)
Number of subjects: 129
Study 36863390 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-food elimination diet (6FED) after 1FED non-responders
Number of subjects: 129
Study 36863390 — intervention group
Group type: EXPERIMENTAL
Intervention: Swallowed topical fluticasone propionate 880 μg twice per day after 6FED non-responders
Number of subjects: 129
Study 36863414 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered parent training (iComet)
Number of subjects: 161
Study 36863414 — intervention group
Group type: COMPARATOR
Intervention: Group-delivered parent training (gComet)
Number of subjects: 161
Study 36863645 — intervention group
Group type: EXPERIMENTAL
Intervention: Preeclampsia
Number of subjects: 1563
Study 36863645 — intervention group
Group type: COMPARATOR
Intervention: Normotensive pregnancy (Control)
Number of subjects: 1563
Study 36863737 — intervention group
Group type: EXPERIMENTAL
Intervention: User-operated Audiometry (UAud)
Number of subjects: 250
Study 36863737 — intervention group
Group type: COMPARATOR
Intervention: Traditional audiometry
Number of subjects: 250
Study 36863737 — intervention group
Group type: EXPERIMENTAL
Intervention: User-operated ACT test
Number of subjects: 250
Study 36863739 — intervention group
Group type: EXPERIMENTAL
Intervention: Active whole-house UV device
Number of subjects: 908
Study 36863739 — intervention group
Group type: COMPARATOR
Intervention: Sham (inactive UV device)
Number of subjects: 908
Study 36863864 — intervention group
Group type: EXPERIMENTAL
Intervention: UC plus motivational interviewing (MI)
Number of subjects: 514
Study 36863864 — intervention group
Group type: EXPERIMENTAL
Intervention: UC plus a stratified vocational advice intervention (SVAI)
Number of subjects: 514
Study 36863864 — intervention group
Group type: COMPARATOR
Intervention: usual case management (UC)
Number of subjects: 514
Study 36863860 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapists' first impression of treatment motivation
Number of subjects: 154
Study 36863897 — intervention group
Group type: EXPERIMENTAL
Intervention: Adoptive transfer of γδ T lymphocytes from haploidentical donors after lymphodepletion regimen
Number of subjects: 0
Study 36864377 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile health technology-based follow-up programme with monthly individualized digital conversations with a PT and activity tracker; additional digital follow-up from a nutritional specialist for those at nutritional risk.
Number of subjects: 100
Study 36864377 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 100
Study 36864394 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants
Number of subjects: 1296
Study 36864394 — intervention group
Group type: COMPARATOR
Intervention: Non-participants
Number of subjects: 1296
Study 36864520 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-hospital trauma feasibility study
Number of subjects: 23
Study 36864569 — intervention group
Group type: EXPERIMENTAL
Intervention: Washed microbiota transplantation (WMT)
Number of subjects: 259
Study 36864622 — intervention group
Group type: EXPERIMENTAL
Intervention: RO5459072 (100 mg twice daily; 200 mg per day)
Number of subjects: 75
Study 36864622 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 36864635 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messaging intervention added to ongoing social and behavioural change (SBC) interventions
Number of subjects: 0
Study 36864635 — intervention group
Group type: COMPARATOR
Intervention: Ongoing social and behavioural change (SBC) interventions without text messaging
Number of subjects: 0
Study 36864699 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual ovarian stimulation (duostim)
Number of subjects: 88
Study 36864699 — intervention group
Group type: COMPARATOR
Intervention: Two consecutive antagonist cycles (control)
Number of subjects: 88
Study 36864701 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-alcoholic fatty liver disease fibrosis score (NFS)
Number of subjects: 3212
Study 36864701 — intervention group
Group type: EXPERIMENTAL
Intervention: BARD score
Number of subjects: 3212
Study 36864701 — intervention group
Group type: EXPERIMENTAL
Intervention: AST/ALT ratio
Number of subjects: 3212
Study 36864701 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Utilities Index (HUI) scores
Number of subjects: 3212
Study 36864701 — intervention group
Group type: EXPERIMENTAL
Intervention: NFS
Number of subjects: 3212
Study 36864705 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme replacement therapy (ERT) with a1-glucosidase alfa
Number of subjects: 6
Study 36864830 — intervention group
Group type: EXPERIMENTAL
Intervention: Early AMD
Number of subjects: 434
Study 36864830 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate AMD
Number of subjects: 434
Study 36864830 — intervention group
Group type: COMPARATOR
Intervention: Normal
Number of subjects: 434
Study 36864830 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma L and Z
Number of subjects: 434
Study 36864830 — intervention group
Group type: EXPERIMENTAL
Intervention: MPOV
Number of subjects: 434
Study 36864830 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of MPOV with plasma L and Z
Number of subjects: 434
Study 36864892 — intervention group
Group type: EXPERIMENTAL
Intervention: Finerenone
Number of subjects: 919
Study 36864892 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 919
Study 36864892 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 919
Study 36864979 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol 300 mg twice daily
Number of subjects: 464
Study 36864979 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 464
Study 36864985 — intervention group
Group type: EXPERIMENTAL
Intervention: ACBMNCs infusion
Number of subjects: 62
Study 36864985 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 62
Study 36865012 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with newly diagnosed CLI
Number of subjects: 1136
Study 36865012 — intervention group
Group type: COMPARATOR
Intervention: Patients without CLI
Number of subjects: 1136
Study 36865055 — intervention group
Group type: EXPERIMENTAL
Intervention: Camrelizumab plus chemotherapy
Number of subjects: 0
Study 36865055 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 0
Study 36865121 — intervention group
Group type: EXPERIMENTAL
Intervention: EM Talk communication skills training (4-hour session with role-plays and active learning)
Number of subjects: 879
Study 36865121 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-intervention survey reflections
Number of subjects: 879
Study 36865133 — intervention group
Group type: EXPERIMENTAL
Intervention: CG-806
Number of subjects: 0
Study 36865151 — intervention group
Group type: EXPERIMENTAL
Intervention: REDCap
Number of subjects: 0
Study 36865151 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 36865179 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapists' care of mental health clients, including their wellbeing and experiences in treatment.
Number of subjects: 150
Study 36865179 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated research and practice within the Mekong Project.
Number of subjects: 150
Study 36865245 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality intervention targeting distress and anxiety
Number of subjects: 0
Study 36865245 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 36865252 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive systolic blood pressure treatment to goal < 120 mm Hg
Number of subjects: 610
Study 36865252 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment to goal < 140 mm Hg
Number of subjects: 610
Study 36865252 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium channel blockers (CCB)
Number of subjects: 610
Study 36865252 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretics
Number of subjects: 610
Study 36865545 — intervention group
Group type: EXPERIMENTAL
Intervention: NK cell-based adoptive immunotherapy from HLA-haploidentical donors
Number of subjects: 0
Study 36865545 — intervention group
Group type: COMPARATOR
Intervention: Standard methodology based on frequency of NK cell clones
Number of subjects: 0
Study 36865545 — intervention group
Group type: COMPARATOR
Intervention: Alternative approach of phenotypic identification of NK cells
Number of subjects: 0
Study 36865634 — intervention group
Group type: EXPERIMENTAL
Intervention: STEADY-PD III
Number of subjects: 998
Study 36865634 — intervention group
Group type: COMPARATOR
Intervention: SURE-PD3
Number of subjects: 998
Study 36865667 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% diclofenac long duration sonophoresis (LDS) daily for 4 weeks
Number of subjects: 135
Study 36865870 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboxytherapy
Number of subjects: 31
Study 36865870 — intervention group
Group type: COMPARATOR
Intervention: Microneedling with topical glutathione
Number of subjects: 31
Study 36866155 — intervention group
Group type: COMPARATOR
Intervention: Retinal arterial and venous vessels in patients with POAG
Number of subjects: 0
Study 36866155 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuronal activation
Number of subjects: 0
Study 36866155 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic vasoconstriction
Number of subjects: 0
Study 36866389 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegbelfermin
Number of subjects: 0
Study 36866412 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib plus pembrolizumab
Number of subjects: 352
Study 36866469 — intervention group
Group type: EXPERIMENTAL
Intervention: myo-inositol, probiotics, and additional micronutrients
Number of subjects: 1729
Study 36866471 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based lifestyle intervention promoting diet, exercise, and self-monitoring of obesity-related behaviours for 9 months
Number of subjects: 30529
Study 36866471 — intervention group
Group type: COMPARATOR
Intervention: Control group with no promotion
Number of subjects: 30529
Study 36866471 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based lifestyle intervention
Number of subjects: 30529
Study 36866658 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (simultaneous use of SCS that does and does not produce tingling sensation)
Number of subjects: 0
Study 36866658 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy (only SCS therapy producing tingling sensation)
Number of subjects: 0